---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-035600"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2023-10-31T23:59:59+00:00"
generated_at: "2026-06-09T04:37:56.419993+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Avalo completes divestiture of AVTX-800 series for $150K upfront, up to $45M milestones

## Summary
- Upfront payment of $150,000 from AUG; AUG assumed $150,000 of pre-closing liabilities.
- Potential aggregate milestone payments of $45M ($15M per compound) upon first FDA approval for non-Rare Pediatric Disease.
- AUG to share up to 20% of net proceeds from any future sale of priority review vouchers.
- CEO states pipeline now focused on core immunology assets; transaction immediately improves cash flow.

## SEC filing metadata
- accession: 0001628280-23-035600
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2023-10-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.01, 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828023035600/0001628280-23-035600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828023035600/avtx-20231027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-035600
- JSON: https://secwatch.observer/filing/0001628280-23-035600.json
- Plain text: https://secwatch.observer/filing/0001628280-23-035600.txt

## Key facts
- M&A Transactions
  Avalo Therapeutics, Inc. completed a disposition involving AUG Therapeutics, LLC for $150,000 upfront plus contingent milestone payments (closed 2023-10-27).
  - Action: disposition
  - Counterparty: AUG Therapeutics, LLC
  - Consideration: $150,000 upfront plus contingent milestone payments
  - Closing: 2023-10-27
  source text: previously announced it entered into a purchase agreement with AUG to divest the 800 Series on September 12, 2023 (the Purchase Agreement). AUG paid an upfront payment of $150,000, as well as, for each compound, is obligated to make a contingent milestone payment of $15,000,000 (for a potential aggregate of $45 million) if the first Food and Drug
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828023035600/0001628280-23-035600-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.